PNEUMAGEN

Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.

PNEUMAGEN

Industry:

Biotechnology Health Care Wellness

Founded:

2016-01-01

Address:

Saint Andrews, Fife, United Kingdom

Country:

United Kingdom

Website Url:

http://www.pneumagen.com

Total Employee:

Status:

Active

Email Addresses:

[email protected]

Total Funding:

10.3 M GBP

Similar Organizations

pandion-therapeutics-logo

Pandion Therapeutics

Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.

Current Advisors List

mark-bamforth_image

Mark Bamforth Board Member @ Pneumagen
Board_member
2020-05-01

Current Employees Featured

douglas-thomson_image

Douglas Thomson
Douglas Thomson Chief Executive Officer @ Pneumagen
Chief Executive Officer

helen-connaris_image

Helen Connaris
Helen Connaris Co-founder and Chief Scientific Officer @ Pneumagen
Co-founder and Chief Scientific Officer

garry-taylor_image

Garry Taylor
Garry Taylor Director and Chairman of Scientific Advisory Board @ Pneumagen
Director and Chairman of Scientific Advisory Board

Founder

garry-taylor_image

Garry Taylor

helen-connaris_image

Helen Connaris

Investors List

scottish-enterprise_image

Official Site Inspections

http://www.pneumagen.com Semrush global rank: 5.19 M Semrush visits lastest month: 1.56 K

Host Informations
Whois Informations

Loading ...